<DOC>
	<DOCNO>NCT00024115</DOCNO>
	<brief_summary>RATIONALE : The BL22 immunotoxin locate tumor cell kill without harm normal cell . PURPOSE : Phase I trial study effectiveness BL22 immunotoxin treat patient non-Hodgkin 's lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>BL22 Immunotoxin Treating Patients With Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity therapeutic efficacy recombinant BL22 immunotoxin patient CD22-positive B-cell non-Hodgkin 's lymphoma chronic lymphocytic leukemia . - Determine pharmacokinetics , include terminal elimination serum half-life area curve volume distribution , recombinant BL22 immunotoxin patient . - Determine immunogenicity recombinant BL22 immunotoxin patient . - Determine effect recombinant BL22 immunotoxin various component circulate cellular immune system patient . OUTLINE : This dose-escalation study . Patients receive recombinant BL22 immunotoxin IV 30 minute day 1 , 3 , 5 . Patients may retreat least every 20 day 25 course absence disease progression sufficient neutralize antibody . Cohorts 3-6 patient receive escalate dos recombinant BL22 immunotoxin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm chronic lymphocytic leukemia prolymphocytic leukemia : Failed prior standard chemotherapy treatment medically indicate evidenced following : Progressive diseaserelated symptom Progressive cytopenia due marrow involvement Progressive painful splenomegaly adenopathy Rapidly increase lymphocytosis Autoimmune hemolytic anemia thrombocytopenia Increased frequency infection OR Confirmed CD22+ Bcell indolent nonHodgkin 's lymphoma Stages IIIV fail least 1 prior standard therapy treatment medically indicate No patient whose serum neutralizes BL22 PE38 tissue culture , due antitoxin antimouseIgG antibodies No central nervous system disease require treatment If patient nonleukemic , absolute neutrophil count must great 1,000/mm3 platelet count great 40,000/mm3 PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 6 month Hematopoietic : See Disease Characteristics Hepatic : ALT AST less 5 time upper limit normal Renal : Adequate renal function Pulmonary : Adequate pulmonary function Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Prior bone marrow transplantation allow At least 3 week since prior interferon malignancy Chemotherapy : See Disease Characteristics At least 3 week since prior cytotoxic chemotherapy malignancy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy malignancy Surgery : Not specify Other : At least 3 week since prior retinoids At least 3 week since prior systemic therapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade I follicular small cleave cell lymphoma</keyword>
	<keyword>stage III grade II follicular mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV grade I follicular small cleave cell lymphoma</keyword>
	<keyword>stage IV grade II follicular mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent grade I follicular small cleave cell lymphoma</keyword>
	<keyword>recurrent grade II follicular mix cell lymphoma</keyword>
	<keyword>recurrent grade III follicular large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult diffuse small noncleaved cell/Burkitt 's lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>contiguous stage II grade I follicular small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II grade II follicular mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade I follicular small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade II follicular mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III diffuse small lymphocytic/marginal zone lymphoma</keyword>
	<keyword>contiguous stage II diffuse small lymphocytic/marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II diffuse small lymphocytic/marginal zone lymphoma</keyword>
	<keyword>stage IV diffuse small lymphocytic/marginal zone lymphoma</keyword>
	<keyword>recurrent diffuse small lymphocytic/marginal zone lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>